ArticleFrontiers in pediatrics2026
Clinical value of neutrophil-to-lymphocyte ratio and D-dimer in predicting the efficacy of minocycline for pediatric Mycoplasma pneumoniae pneumonia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children. With the increasing prevalence of macrolide-resistant strains, minocycline has become a crucial alternative treatment. However, there is a lack of early predictive markers for evaluating early clinical response. This study aimed to investigate the clinical value of the neutrophil-to-lymphocyte ratio (NLR) and D-dimer levels in predicting early clinical response to minocycline in pediatric MPP. Methods: A retrospective analysis was conducted on 86 children aged 8-14 years with MPP who received minocycline treatment at Tianjin University Central Hospital between January 2023 and January 2025. Treatment efficacy was defined based on the body temperature response within 48 h after initiating minocycline: patients whose body temperature returned to normal (≤37.3 °C) were classified as having effective treatment (responsive group, Results: The non-responsive group exhibited significantly higher NLR (median 2.62 vs. 1.69, Conclusion: NLR and D-dimer are reliable and accessible biomarkers for predicting early clinical response to minocycline in pediatric MPP. Elevated baseline levels identify patients at risk for persistent fever and need for treatment escalation. Their combined detection offers high clinical value, facilitating early identification of poor responders and timely adjustment of therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.